4. Echoes of the Deal

Six months before the burning car in the mountains, before the locked room in Sorok Psychiatric Hospital, before the electrodes and the sedatives and the desperate recitation of prime numbers, Park Min-jun had stood in the boardroom of Keihai Tech and watched his dream begin to die.

It was a Tuesday afternoon in late autumn, the kind of day when the light over Seorae turned golden and melancholy, slanting through the floor-to-ceiling windows of the Taisei Building's fifth floor. Min-jun had loved this view when they first leased the space—the sweep of the city spreading toward the harbor, the distant smudge of mountains, the sense that he was standing at the edge of something vast and full of possibility. He had been thirty-two then, three years out of graduate school, with a prototype algorithm and a conviction that technology could make medicine safer, smarter, more humane.

Eight years later, he was forty, and the view looked different. The mountains were still there, the harbor still glinted in the afternoon sun, but the possibility had curdled into something else. Doubt. Exhaustion. The slow, grinding realization that building something good was not the same as building something that could survive.

The boardroom was occupied by three people: Min-jun himself, seated at the head of the polished oak table; Jo Sang-cheol, his co-founder and CEO, who stood by the window with his back to the room; and a man Min-jun had never met before, a compact figure in an expensive suit who had introduced himself simply as “Mr. Yamamoto” and whose business card bore only a phone number and the name of a consulting firm that Min-jun could not find in any corporate registry.

“The clinical trial results came back this morning,” Sang-cheol was saying, still facing the window. “Phase three. The cardiac prediction algorithm failed to meet its primary endpoint. False positives were higher than expected. The efficacy data is... not what we hoped.”

Min-jun had known this was coming. He had been tracking the trial data for months, watching the numbers drift in the wrong direction, hoping for a turnaround that never materialized. The algorithm was not bad—it was actually quite good by most standards, better than anything else on the market. But “better than anything else” was not enough for regulatory approval. The medical devices agency wanted near-perfection, and perfection was not something Min-jun could promise.

“How bad is it?” he asked.

Sang-cheol finally turned from the window. His face was composed, but Min-jun had known him for fifteen years and could read the tension in the set of his jaw. “Bad enough that our lead investor is pulling out. They informed me this morning. Without their capital, we can't fund another trial. Without another trial, we can't get approval. Without approval, we have no revenue. Without revenue...” He spread his hands. “We have about three months of runway left. After that, we're done.”

Min-jun absorbed this information in silence. He thought about the seventy-four employees who depended on Keihai Tech for their livelihoods. He thought about the years of research, the sleepless nights, the incremental breakthroughs that had felt, at the time, like victories. He thought about his mother, who had died of a cardiac event that a better monitoring system might have predicted, and whose death had been the spark that ignited his career.

“There has to be another option,” he said. “A bridge round. A strategic partner. Something.”

“That's why I asked Mr. Yamamoto to join us today.” Sang-cheol gestured toward the stranger, who had been observing the exchange with the patient stillness of a man who was accustomed to letting others do the talking. “His organization has expressed interest in acquiring a controlling stake in Keihai Tech.”

Min-jun looked at Yamamoto. The man's suit was expensive but understated—charcoal gray, perfectly tailored, no visible branding. His hair was cropped short in a style that suggested military discipline. His hands, folded on the table in front of him, were thick-knuckled and scarred in ways that did not align with his claimed profession as a consultant.

“What kind of organization?” Min-jun asked.

Yamamoto smiled. It was a practiced smile, the smile of a man who had answered this question many times and had learned to make his answer sound reassuring. “We are a private investment consortium based in Osaka. We specialize in turnaround situations—companies with strong underlying technology that are facing temporary financial difficulties. We provide capital and operational support. In exchange, we take a majority equity position and board control.”

“And your track record?”

“We have successfully restructured seventeen companies in the past decade. Most of them remain in operation. Several have gone on to significant profitability.” Yamamoto paused, and something flickered in his eyes—something that might have been amusement, or might have been the opposite. “We are very good at what we do, Mr. Park. We solve problems that other investors cannot solve.”

Min-jun turned to Sang-cheol. “Can I speak with you privately?”

They stepped into the hallway, leaving Yamamoto alone in the boardroom. The fluorescent lights of the corridor hummed at a frequency that made Min-jun's teeth ache, and he felt a headache beginning to build behind his eyes.

“Who are these people really?” he asked. “I ran a background check on the consulting firm. It doesn't exist. The phone number on the card traces back to a holding company that traces back to another holding company that traces back to a post office box in the Cayman Islands. This isn't a legitimate investment consortium.”

Sang-cheol's expression hardened. “You think I don't know that? You think I haven't spent the past two weeks doing exactly the same research? I know who they are. I know where their money comes from. I also know that without their money, this company is dead in three months.”

“Then let it die. We can start over. We can find other investors.”

“There are no other investors, Min-jun. I've pitched every venture capital firm in this country. I've talked to strategic buyers, private equity funds, sovereign wealth funds. Nobody wants to touch a medical AI company with a failed phase three trial. We're toxic.” Sang-cheol's voice dropped, taking on an intensity that bordered on desperation. “This is the only offer on the table. If we don't take it, we lose everything. Not just the company—everything. The patents, the technology, the years of work. It all gets sold off in a bankruptcy auction to the highest bidder, and we walk away with nothing.”

“So instead we walk away with blood money?”

“We walk away with a chance to finish what we started. Yamamoto's people don't care about quarterly reports. They're patient investors. They'll give us the time we need to fix the algorithm, to run another trial, to get approval. Once we're profitable, we can buy them out. It's a bridge, Min-jun. That's all. A bridge to the other side of this mess.”

Min-jun looked at his oldest friend—the man he had met in a cramped dormitory room during their first year of university, who had stayed up with him through countless nights debugging code and refining algorithms, who had believed in the vision of Keihai Tech when no one else would—and felt something fracture between them. Not a clean break, but a hairline crack that would widen over time until it became an abyss.

“These people don't give bridges,” he said quietly. “They give chains. Once we're in business with them, we'll never get out. You know that. I know you know that.”

Sang-cheol held his gaze for a long moment. Then he looked away.

“The board meeting is tomorrow,” he said. “I have the votes to approve the acquisition without your consent. I didn't want to do it that way, but I will if I have to. This company is bigger than either of us now. It's bigger than our friendship. It's bigger than your principles.”

He turned and walked back into the boardroom, leaving Min-jun alone in the humming corridor, staring at the closed door and the world he had built dissolving on the other side of it.

The acquisition went through. The board voted five to two in favor, with Min-jun casting one of the dissenting votes and an independent director casting the other. Sang-cheol, as CEO and chairman, signed the final documents at a ceremony that Min-jun refused to attend. The company received an infusion of capital—enough to keep the lights on for another eighteen months—and a new board of directors composed largely of Yamamoto's associates.

For a while, things seemed almost normal. The new board members were polite and unobtrusive. They attended meetings, asked occasional questions, and otherwise left the management team alone. The engineering department continued to refine the algorithm. The business development team began courting potential customers in markets where regulatory requirements were less stringent. Sang-cheol assured everyone that the turnaround was working, that the company was on track, that the darkest days were behind them.

But Min-jun was watching. And what he saw disturbed him more than he could easily articulate.

It started with small things. A change in the software specifications that routed patient data through an external server. A decision to fast-track the algorithm's deployment in certain overseas markets without the customary validation studies. A series of meetings between Sang-cheol and Yamamoto that were not recorded in any corporate calendar and that seemed to produce decisions without any paper trail.

Then came the subcontractors. Min-jun discovered them almost by accident, while reviewing a quarterly expense report. The company was paying substantial sums to three different consulting firms—firms that had no web presence, no listed employees, and no apparent function. When he traced the payments, he found that the money was flowing through a series of intermediary accounts before being deposited into an entity called Seongjin Holdings.

He spent a week digging deeper, working late into the night while the office emptied around him. What he found made his blood run cold.

The subcontractors were shell companies. The payments were being siphoned out of Keihai Tech's research and development budget and funnelled into accounts controlled by a criminal organization called the Kuroda-gumi—a syndicate with interests in construction, shipping, gambling, and, apparently, medical technology. The patient data that had been routed through external servers was being packaged and sold to insurance companies and pharmaceutical manufacturers without patient consent. The algorithm that Min-jun had designed to save lives was being repurposed to deny insurance coverage and inflate drug prices.

His dream had not just died. It had been resurrected as something monstrous.

He confronted Sang-cheol in the office one night, long after the cleaning crew had come and gone. He laid out the evidence on the conference table: the shell companies, the data sales, the Kuroda-gumi connection. He demanded that Sang-cheol come with him to the police, to the regulatory agencies, to anyone who would listen.

Sang-cheol listened to him in silence. Then he poured two glasses of whiskey from the bottle he kept in his desk drawer and pushed one across the table.

“You've been under a lot of stress lately,” he said. “We all have. The turnaround has been harder than anyone expected. Maybe you should take some time off. A leave of absence. Get some rest.”

“I don't need rest. I need you to tell me that what I found isn't true.”

Sang-cheol took a sip of his whiskey. His hand was steady. His expression was calm.

“What you found is true,” he said. “All of it. The data sales, the shell companies, the Kuroda-gumi. I've known about it for months. I approved most of it myself.”

The admission hit Min-jun like a physical blow. He had expected denial, deflection, perhaps even anger. He had not expected honesty.

“Why?” he managed to ask. “We were building something good. Something that could have helped people.”

“We were building a company that was going to go bankrupt. Now we're building a company that's going to survive. The algorithm is still there, Min-jun. It's still going to help people, eventually. But first we have to get through the next eighteen months. First we have to pay back the people who gave us the money to keep going. That's not a choice. That's a necessity.”

“It's a crime. You're committing crimes. We're committing crimes.”

Sang-cheol set down his glass and looked at Min-jun with an expression that was almost pitying. “We committed our first crime the day we took Yamamoto's money. Everything after that is just details.” He stood, straightening his jacket. “Take the leave of absence, Min-jun. Go somewhere. Forget about the books and the servers and the shell companies. When you come back, the company will still be here. Your equity will still be here. Everything you've worked for will still be here. The only thing that will be different is that you'll have learned to live with the world as it actually is, instead of the world as you wish it were.”

Min-jun did not take the leave of absence. Instead, he went to the auditors.

The auditors were a husband-and-wife team, forensic accountants who had built a reputation for uncovering fraud in the technology sector. They were thorough, meticulous, and utterly fearless—qualities that had earned them both respect and enemies. Min-jun met them in a cafe in a neighborhood where no one from Keihai Tech was likely to see him, and he laid out everything he had found.

They spent three weeks investigating. At the end of those three weeks, they had assembled a dossier that was even more damning than what Min-jun had discovered on his own. The Kuroda-gumi was not just siphoning money from Keihai Tech; they were using the company as a front for a much larger operation that involved multiple startups, several hospitals, and at least one government regulatory agency. The data being sold was being used to manipulate clinical trials and inflate drug prices on a scale that affected millions of patients.

“This is going to bring down a lot of people,” the husband said, sliding the dossier across the table. “Are you ready for that?”

Min-jun thought about Sang-cheol, about the years of friendship, about the company they had built together. He thought about his mother, and the cardiac event that had killed her, and the patients who were being harmed by the very technology he had designed to help them.

“Yes,” he said. “I'm ready.”

The auditors scheduled a meeting with Keihai Tech's legal counsel for the following week. They never made it to that meeting. Two days later, their car was found burning in a ravine in the mountains north of Seorae, and Min-jun's phone began to buzz with calls he knew better than to answer.

He spent the next forty-eight hours in hiding, moving between cheap motels and internet cafes, trying to figure out what to do next. He had copies of the dossier—not all of it, but enough to be dangerous. He had contacts at a national newspaper who might be willing to run the story. He had a lawyer who had agreed to represent him if things went bad.

But before he could make any of those moves, Sang-cheol found him. Not Sang-cheol personally, but the men who worked for Yamamoto, who appeared in his motel room in the middle of the night with a syringe and a bag over his head and the calm, practiced efficiency of people who had done this before.

The last thing Min-jun remembered before the darkness swallowed him was Sang-cheol's voice, somewhere in the distance, saying something he couldn't quite make out. It might have been an apology. It might have been a curse. It might have been nothing at all.

In Sorok Psychiatric Hospital, Min-jun opened his eyes.

The memory had come to him in fragments, surfacing through the sedative haze like wreckage rising from a sunken ship. He was not sure how long he had been lying there, drifting between sleep and waking, but the pencil stub was still hidden beneath his mattress and the camera in the corner was still blinking its red eye and somewhere down the corridor a patient was wailing in a language that might have been Korean or might have been the private language of madness.

He reached under the mattress and retrieved the pencil. Then, very carefully, he began to write on the underside of the bed frame, where the orderlies never looked and the cameras could not see.

Seongjin Holdings. Kuroda-gumi. Data sales. Clinical trials. Auditors.

The words were shaky and uneven, the handwriting of a man whose fine motor control had been compromised by electricity and chemicals. But they were legible. They were real. They were proof that the memories still existed, even if the pathways to reach them were growing fainter by the day.

He was still writing when the door opened and an orderly entered with the morning medication.

“Time for your pills, Mr. Park.”

Min-jun slid the pencil back under the mattress and took the paper cup. He swallowed the pills without protest, and he smiled at the orderly, and he said nothing at all.

Because he had learned something in the weeks since his commitment, something that Sang-cheol and Yamamoto and even Dr. Miura had not anticipated. He had learned how to wait. He had learned how to hide pieces of himself in places where the electricity could not reach. He had learned that survival was not about fighting back—it was about enduring long enough for the fight to find you.

And somewhere out there, in the city beyond the barred window and the razor-wire walls, Detective Kang Joon-suh was still looking for him.

Min-jun closed his eyes and waited for the medication to take hold, and in the darkness behind his eyelids, he continued to write.